Personalized lung cancer treatment aims to spare patients harsh chemo
NCT ID NCT07241819
Summary
This study is testing a drug called ivonescimab, given alone or with chemotherapy, to treat patients with non-small cell lung cancer that can be removed by surgery. The goal is to see if using less chemotherapy based on a patient's tumor marker (PD-L1) can reduce side effects while still effectively controlling the cancer before and after the operation. About 66 patients will participate to see how well the treatment works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for II-IIIB (T3N2) RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.